摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-溴-3-三氟甲基吡唑 | 19968-17-3

中文名称
4-溴-3-三氟甲基吡唑
中文别名
4-溴-3-三氟甲基-1H-吡唑
英文名称
4-bromo-3-(trifluoromethyl)-1H-pyrazole
英文别名
4-bromo-5-(trifluoromethyl)-1H-pyrazole
4-溴-3-三氟甲基吡唑化学式
CAS
19968-17-3
化学式
C4H2BrF3N2
mdl
MFCD04969230
分子量
214.972
InChiKey
JTHNMRUVJDWVMJ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    105-107℃
  • 沸点:
    235.3±35.0 °C(Predicted)
  • 密度:
    1.942±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.8
  • 重原子数:
    10
  • 可旋转键数:
    0
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.25
  • 拓扑面积:
    28.7
  • 氢给体数:
    1
  • 氢受体数:
    4

安全信息

  • 危险等级:
    IRRITANT
  • 危险品标志:
    Xi,C
  • 海关编码:
    2933199090
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H335

SDS

SDS:034e5c20e1eba62063ce92662ce25e53
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 4-Bromo-3-(trifluoromethyl)-1H-pyrazole
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H301: Toxic if swallowed
P301+P310: IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician

Section 3. Composition/information on ingredients.
Ingredient name: 4-Bromo-3-(trifluoromethyl)-1H-pyrazole
CAS number: 19968-17-3

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C4H2BrF3N2
Molecular weight: 215.0

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen fluoride, hydrogen bromide.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
UN Number: UN2811 Class: 6.1 Packing group: III
Proper shipping name: TOXIC SOLIDS, ORGANIC, N.O.S. (4-Bromo-3-(trifluoromethyl)-1H-pyrazole)

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    NITROGENOUS FUSED-RING COMPOUND HAVING PYRAZOLYL GROUP AS SUBSTITUENT AND MEDICINAL COMPOSITION THEREOF
    摘要:
    公开号:
    EP1382603B1
  • 作为产物:
    描述:
    3-(三氟甲基)吡唑1,3-二溴-5,5-二甲基海因 作用下, 以 乙腈 为溶剂, 以2.1 g的产率得到4-溴-3-三氟甲基吡唑
    参考文献:
    名称:
    [EN] BENZIMIDAZOLE COMPOUND OR SALT THEREOF, DIROFILARIASIS PREVENTION AGENT CONTAINING BENZIMIDAZOLE COMPOUND, AND USAGE METHOD FOR DIROFILARIASIS PREVENTION AGENT
    [FR] COMPOSÉ DE BENZIMIDAZOLE OU SEL DE CELUI-CI, AGENT DE PRÉVENTION DE LA DIROFILARIOSE CONTENANT UN COMPOSÉ DE BENZIMIDAZOLE, ET PROCÉDÉ D'UTILISATION DE L'AGENT DE PRÉVENTION DE LA DIROFILARIOSE
    [JA] ベンゾイミダゾール化合物又はその塩類及び該化合物を含有する犬糸状虫症防除剤並びにその使用方法
    摘要:
    本发明的目的是提供一种对目标动物投与并具有优异效果的动物用犬钩虫症防治剂以及使用该防治剂的动物的犬钩虫症防治剂的使用方法。本发明提供了以通式(1)(其中,R表示氢原子、烷基等,Y1、Y2、Y3和Y4表示氢原子、卤素原子等,X1、X2和X3表示氢原子、卤素原子、烷基或卤代烷基)表示的苯并咪唑化合物或其盐类为有效成分的动物用犬钩虫症防治剂及其使用方法。
    公开号:
    WO2022255461A1
点击查看最新优质反应信息

文献信息

  • 杂芳化合物及其在药物中的应用
    申请人:广东东阳光药业有限公司
    公开号:CN106749268B
    公开(公告)日:2020-10-09
    本发明公开了杂芳化合物及其在药物中的应用,具体地,本发明提供一类杂芳化合物或其立体异构体,几何异构体,互变异构体,消旋体,氮氧化物,水合物,溶剂化物,代谢产物,药学上可接受的盐或前药,以及包含所述化合物的药物组合物;本发明还公开了所述化合物或其药物组合物在制备药物中的用途,及其在治疗自体免疫疾病或增殖性疾病方面的应用。
  • [EN] PYRAZOLE CARBOXAMIDE COMPOUNDS FOR TREATMENT OF HBV<br/>[FR] COMPOSÉS DE PYRAZOLE CARBOXAMIDE POUR LE TRAITEMENT DU VHB
    申请人:ASSEMBLY BIOSCIENCES INC
    公开号:WO2021216642A1
    公开(公告)日:2021-10-28
    The present disclosure provides, in part, pyrazole carboxamide compounds, and pharmaceutical compositions thereof, useful for disruption of HBV core protein assembly, and methods of treating Hepatitis B (HBV) infection.
    本公开提供了吡唑羧酰胺化合物及其药物组合物,用于破坏HBV核心蛋白的组装,并治疗乙型肝炎(HBV)感染的方法。
  • Palladium‐ and Rhodium‐Catalyzed Dynamic Kinetic Resolution of Racemic Internal Allenes Towards Chiral Pyrazoles
    作者:Lukas J. Hilpert、Simon V. Sieger、Alexander M. Haydl、Bernhard Breit
    DOI:10.1002/anie.201812984
    日期:2019.3.11
    resolution (DKR) of racemic allenes leading to N‐allylated pyrazoles is described. Such compounds are of enormous interest in medicinal chemistry as certified drugs and potential drug candidates. The new methods feature high chemo‐, regio‐ and enantioselectivities aside from displaying a broad substrate scope and functional group compatibility. A mechanistic rational accounting for allene racemization and trans‐alkene
    描述了外消旋烯的互补的Pd和Rh催化的动态动力学拆分(DKR),导致N-烯丙基化的吡唑。这类化合物作为认证药物和潜在候选药物在药物化学中引起了极大的兴趣。这些新方法除了具有广泛的底物范围和官能团相容性外,还具有较高的化学,区域和对映选择性。讨论了合理的机制来解释异戊二烯外消旋和反式烯烃的选择性。
  • PYRROLOPYRIDINE RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR MODULATORS AND USES THEREOF
    申请人:INNOV17 LLC
    公开号:US20170298060A1
    公开(公告)日:2017-10-19
    Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of Retinoic Acid Receptor-Related Orphan Receptor regulated diseases and disorders.
    本文提供了以下式(I)的化合物: 以及其药学上可接受的盐,其中取代基如规范中所披露的那样。这些化合物及含有它们的药物组合物对于治疗与视黄酸受体相关孤儿受体调节的疾病和紊乱是有用的。
  • Fused Bicyclic Kinase Inhibitors
    申请人:Mulvihill Mark J.
    公开号:US20110281888A1
    公开(公告)日:2011-11-17
    Compounds of Formula I, as shown below and defined herein: pharmaceutically acceptable salts thereof, synthesis, intermediates, formulations, and methods of disease treatment therewith, including treatment of cancers, such as tumors driven at least in part by at least one of RON, MET or ALK. This Abstract is not limiting of the invention.
    公式I的化合物如下所示并在此定义: 其药用可接受盐、合成、中间体、配方以及使用其进行疾病治疗的方法,包括治疗癌症,如至少部分由RON、MET或ALK驱动的肿瘤。本摘要不限制该发明。
查看更多

同类化合物

试剂2,5-Dibromo-3,4-dihexylthiophene 苯-1,2,4-三羧酸-丙烷-1,2,3-三醇(1:1) 碘吡咯 癸氯-二茂铁 溴代二茂铁 溴-(3-溴-2-噻嗯基)镁 派瑞林D 派瑞林 F 二聚体 氯代二茂铁 曲洛酯 异噻唑,3-氯-5-甲基- 地茂酮 四碘噻吩 四溴噻吩 四溴吡咯 四溴-N-甲基吡咯 四氯噻吩 四氟噻吩 噻菌腈 噻美尼定. 噻吩,3-溴-4-(1-辛炔基)- 噻吩,2,5-二氯-3,4-二(氯甲基)- 喷贝特 咪唑烷,2-(4-溴-5-甲基-2-呋喃基)-1,3-二甲基- 叔丁基2-溴-4,6-二氢-5H-吡咯并[3,4-D]噻唑-5-羧酸酯 叔-丁基2-溴-5,6-二氢咪唑并[1,2-A]吡嗪-7(8H)-甲酸基酯 八氟联苯烯 八氟二苯并硒吩 二苯基氯化碘盐 二联苯碘硫酸盐 二氯对二甲苯二聚体 二氯[2-甲基-3(2H)-异噻唑酮-O]的钙合物 二氯-1,2-二硫环戊烯酮 二-(3-溴-1,2,4-噻二唑-5-基)-二硫醚 二(2-噻吩基)碘鎓 [四丁基铵][Δ-三(四氯-1,2-苯二醇酸根)磷酸盐(V)] [3-(4-氯-3,5-二甲基-1H-吡唑-1-基)丙基]胺 [3-(4-氯-1H-吡唑-1-基)-2-甲基丙基]胺 [2-(4-溴-吡唑-1-基)-乙基]-二甲胺 [1-(4-溴-3-甲基-1,2-噻唑-5-基)乙亚基氨基]硫脲 [1-(4-溴-1,2-噻唑-3-基)乙亚基氨基]硫脲 [1,1'-联苯]-2,2'-二基碘鎓 [(4-碘-1,2-噻唑-5-基)亚甲基氨基]硫脲 [(4-氯-1,2-噻唑-5-基)亚甲基氨基]硫脲 N-苄基-2-氯吡咯 N-Boc-2-氨基-3-溴噻吩 N-(2-氯-4-甲基-3-噻吩)-4,5-二氢-1H-咪唑-2-胺盐酸盐 N-(2,5-二溴-1H-吡咯-1-基)-氨基甲酸叔丁酯 N,N-二甲基-5-碘-1H-吡唑-1-磺酰胺 N,N-二甲基-2-(3,4,5-三溴吡唑-1-基)丙酰胺